Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CLOV stock price vs LSTR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LSTR's multiple
Needs Annual EPS, LSTR P/E.
Implied fair value · at CLOV's multiple
Needs CLOV P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CLOVER HEALTH INVESTMENTS, CORP. /DE · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
LANDSTAR SYSTEM, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Alignment Healthcare, Inc.
CLOV vs ALHC
Oscar Health, Inc.
CLOV vs OSCR
MOLINA HEALTHCARE, INC.
CLOV vs MOH
CENTENE CORP
CLOV vs CNC
Knight-Swift Transportation Holdings Inc.
CLOV vs KNX
C. H. ROBINSON WORLDWIDE, INC.
CLOV vs CHRW
SAIA INC
CLOV vs SAIA
WERNER ENTERPRISES INC
CLOV vs WERN
RYDER SYSTEM INC
CLOV vs R
ARCBEST CORP /DE/
CLOV vs ARCB
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CLOV can convert its 40.3% revenue growth into sustained positive operating and net margins, then the stock looks reasonable to own at $5.26 because LSTR-implied value is $5.60 and the current price is still within its historical band.
CLOV’s current price of $5.26 sits below LSTR-implied price of $5.60, suggesting only 6.4% upside. The stock is also within its historical band of $4.73 to $5.79, so valuation looks fair-to-slightly cheap rather than deeply discounted.
Supporting Metrics
